Johnson & Johnson Long Term Debt 2010-2024 | JNJ

Johnson & Johnson long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
  • Johnson & Johnson long term debt for the quarter ending March 31, 2024 was $25.082B, a 28.19% decline year-over-year.
  • Johnson & Johnson long term debt for 2023 was $25.881B, a 3.74% decline from 2022.
  • Johnson & Johnson long term debt for 2022 was $26.886B, a 10.34% decline from 2021.
  • Johnson & Johnson long term debt for 2021 was $29.985B, a 8.12% decline from 2020.
Johnson & Johnson Annual Long Term Debt
(Millions of US $)
2023 $25,881
2022 $26,886
2021 $29,985
2020 $32,635
2019 $26,494
2018 $27,684
2017 $30,675
2016 $22,442
2015 $12,857
2014 $15,122
2013 $13,328
2012 $11,489
2011 $12,969
2010 $9,156
2009 $8,223
Johnson & Johnson Quarterly Long Term Debt
(Millions of US $)
2024-03-31 $25,082
2023-12-31 $25,881
2023-09-30 $26,051
2023-06-30 $33,901
2023-03-31 $34,928
2022-12-31 $26,886
2022-09-30 $27,603
2022-06-30 $28,292
2022-03-31 $28,851
2021-12-31 $29,985
2021-09-30 $30,130
2021-06-30 $30,310
2021-03-31 $30,263
2020-12-31 $32,635
2020-09-30 $32,680
2020-06-30 $25,062
2020-03-31 $25,393
2019-12-31 $26,494
2019-09-30 $26,919
2019-06-30 $27,699
2019-03-31 $27,660
2018-12-31 $27,684
2018-09-30 $29,480
2018-06-30 $29,405
2018-03-31 $29,837
2017-12-31 $30,675
2017-09-30 $26,675
2017-06-30 $27,363
2017-03-31 $27,015
2016-12-31 $22,442
2016-09-30 $23,546
2016-06-30 $24,535
2016-03-31 $20,233
2015-12-31 $12,857
2015-09-30 $14,073
2015-06-30 $14,085
2015-03-31 $14,938
2014-12-31 $15,122
2014-09-30 $13,152
2014-06-30 $13,303
2014-03-31 $13,343
2013-12-31 $13,328
2013-09-30 $9,748
2013-06-30 $9,643
2013-03-31 $11,363
2012-12-31 $11,489
2012-09-30 $11,428
2012-06-30 $11,525
2012-03-31 $13,010
2011-12-31 $12,969
2011-09-30 $13,031
2011-06-30 $13,680
2011-03-31 $9,255
2010-12-31 $9,156
2010-09-30 $9,182
2010-06-30 $7,937
2010-03-31 $8,059
2009-12-31 $8,223
2009-09-30 $8,259
2009-06-30 $8,179
2009-03-31 $8,052
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $349.955B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $824.287B 119.14
Novo Nordisk (NVO) Denmark $642.884B 49.40
Merck (MRK) United States $329.771B 60.00
AbbVie (ABBV) United States $293.293B 15.15
AstraZeneca (AZN) United Kingdom $248.255B 21.58
Novartis AG (NVS) Switzerland $215.744B 15.30
Pfizer (PFE) United States $156.738B 19.48
Sanofi (SNY) $122.543B 11.56
Innoviva (INVA) United States $0.993B 6.97